{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T02:12:37Z","timestamp":1773108757521,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,9]]},"DOI":"10.7759\/cureus.104920","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T14:30:56Z","timestamp":1773066656000},"source":"Crossref","is-referenced-by-count":0,"title":["Psychosis and Incidental Latent Toxoplasmosis: A Case Report and Key Learning Points"],"prefix":"10.7759","author":[{"given":"Filipa M.A.A.","family":"Teixeira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/epirev\/mxn001","article-title":"Schizophrenia: a concise overview of incidence, prevalence, and mortality","volume":"30","author":"McGrath J","year":"2008","unstructured":"McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008, 30:67-76. 10.1093\/epirev\/mxn001","journal-title":"Epidemiol Rev"},{"key":"ref2","article-title":"Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association.  Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition: DSM-5. American Psychiatric Association Publishing, Washington, D.C.; 2013. https:\/\/ia800707.us.archive.org\/15\/items\/info_munsha_DSM5\/DSM-5.pdf."},{"key":"ref3","article-title":"","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. ICD-11 Implementation or Transition Guide. World Health Organization, Geneva, Switzerland; 2019. https:\/\/icd.who.int\/en\/docs\/ICD-11%20Implementation%20or%20Transition%20Guide_v105.pdf."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.07.011","article-title":"Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990-2017: systematic review and meta-analysis","volume":"191","author":"Hunt GE","year":"2018","unstructured":"Hunt GE, Large MM, Cleary M, Lai HM, Saunders JB. Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990-2017: systematic review and meta-analysis. Drug Alcohol Depend. 2018, 191:234-58. 10.1016\/j.drugalcdep.2018.07.011","journal-title":"Drug Alcohol Depend"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16412-X","article-title":"Toxoplasmosis","volume":"363","author":"Montoya JG","year":"2004","unstructured":"Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet. 2004, 363:1965-76. 10.1016\/S0140-6736(04)16412-X","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199212033272306","article-title":"Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome","volume":"327","author":"Porter SB","year":"1992","unstructured":"Porter SB, Sande MA. Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome. N Engl J Med. 1992, 327:1643-8. 10.1056\/NEJM199212033272306","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12423","article-title":"Beyond the association. Toxoplasma gondii in schizophrenia, bipolar disorder, and addiction: systematic review and meta-analysis","volume":"132","author":"Sutterland AL","year":"2015","unstructured":"Sutterland AL, Fond G, Kuin A, et al.. Beyond the association. Toxoplasma gondii in schizophrenia, bipolar disorder, and addiction: systematic review and meta-analysis. Acta Psychiatr Scand. 2015, 132:161-79. 10.1111\/acps.12423","journal-title":"Acta Psychiatr Scand"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbs043","article-title":"Toxoplasma gondii and other risk factors for schizophrenia: an update","volume":"38","author":"Torrey EF","year":"2012","unstructured":"Torrey EF, Bartko JJ, Yolken RH. Toxoplasma gondii and other risk factors for schizophrenia: an update. Schizophr Bull. 2012, 38:642-7. 10.1093\/schbul\/sbs043","journal-title":"Schizophr Bull"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbr109","article-title":"Imaging biomarkers for treatment development for impaired cognition: report of the sixth CNTRICS meeting: biomarkers recommended for further development","volume":"38","author":"Carter CS","year":"2012","unstructured":"Carter CS, Barch DM. Imaging biomarkers for treatment development for impaired cognition: report of the sixth CNTRICS meeting: biomarkers recommended for further development. Schizophr Bull. 2012, 38:26-33. 10.1093\/schbul\/sbr109","journal-title":"Schizophr Bull"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023866","article-title":"The neurotropic parasite Toxoplasma gondii increases dopamine metabolism","volume":"6","author":"Prandovszky E","year":"2011","unstructured":"Prandovszky E, Gaskell E, Martin H, Dubey JP, Webster JP, McConkey GA. The neurotropic parasite Toxoplasma gondii increases dopamine metabolism. PLoS One. 2011, 6:e23866. 10.1371\/journal.pone.0023866","journal-title":"PLoS One"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3024.2009.01131.x","article-title":"Toxoplasma and schizophrenia","volume":"31","author":"Yolken RH","year":"2009","unstructured":"Yolken RH, Dickerson FB, Fuller Torrey E. Toxoplasma and schizophrenia. Parasite Immunol. 2009, 31:706-15. 10.1111\/j.1365-3024.2009.01131.x","journal-title":"Parasite Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2019.01.026","article-title":"Large-scale study of Toxoplasma and Cytomegalovirus shows an association between infection and serious psychiatric disorders","volume":"79","author":"Burgdorf KS","year":"2019","unstructured":"Burgdorf KS, Trabjerg BB, Pedersen MG, et al.. Large-scale study of Toxoplasma and Cytomegalovirus shows an association between infection and serious psychiatric disorders. Brain Behav Immun. 2019, 79:152-8. 10.1016\/j.bbi.2019.01.026","journal-title":"Brain Behav Immun"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.4.767","article-title":"Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring","volume":"162","author":"Brown AS","year":"2005","unstructured":"Brown AS, Schaefer CA, Quesenberry CP Jr, Liu L, Babulas VP, Susser ES. Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring. Am J Psychiatry. 2005, 162:767-73. 10.1176\/appi.ajp.162.4.767","journal-title":"Am J Psychiatry"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbl074","article-title":"Effects of toxoplasma on human behavior","volume":"33","author":"Flegr J","year":"2007","unstructured":"Flegr J. Effects of toxoplasma on human behavior. Schizophr Bull. 2007, 33:757-60. 10.1093\/schbul\/sbl074","journal-title":"Schizophr Bull"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2013.11.011","article-title":"Evaluation of kynurenine pathway metabolism in Toxoplasma gondii-infected mice: implications for schizophrenia","volume":"152","author":"Notarangelo FM","year":"2014","unstructured":"Notarangelo FM, Wilson EH, Horning KJ, et al.. Evaluation of kynurenine pathway metabolism in Toxoplasma gondii-infected mice: implications for schizophrenia. Schizophr Res. 2014, 152:261-7. 10.1016\/j.schres.2013.11.011","journal-title":"Schizophr Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.5.466","article-title":"Association of serum antibodies to herpes simplex virus 1 with cognitive deficits in individuals with schizophrenia","volume":"60","author":"Dickerson FB","year":"2003","unstructured":"Dickerson FB, Boronow JJ, Stallings C, Origoni AE, Ruslanova I, Yolken RH. Association of serum antibodies to herpes simplex virus 1 with cognitive deficits in individuals with schizophrenia. Arch Gen Psychiatry. 2003, 60:466-72. 10.1001\/archpsyc.60.5.466","journal-title":"Arch Gen Psychiatry"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2006.00780.x","article-title":"Prevalence of Toxoplasma infection in first-episode schizophrenia and comparison between Toxoplasma-seropositive and Toxoplasma-seronegative schizophrenia","volume":"114","author":"Wang HL","year":"2006","unstructured":"Wang HL, Wang GH, Li QY, Shu C, Jiang MS, Guo Y. Prevalence of Toxoplasma infection in first-episode schizophrenia and comparison between Toxoplasma-seropositive and Toxoplasma-seronegative schizophrenia. Acta Psychiatr Scand. 2006, 114:40-8. 10.1111\/j.1600-0447.2006.00780.x","journal-title":"Acta Psychiatr Scand"},{"key":"ref18","unstructured":"Psychosis and schizophrenia in adults. prevention and management. (2014). Accessed: 2025: https:\/\/www.nice.org.uk\/guidance\/cg178."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/464953-psychosis-and-incidental-latent-toxoplasmosis-a-case-report-and-key-learning-points","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T14:30:57Z","timestamp":1773066657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/464953-psychosis-and-incidental-latent-toxoplasmosis-a-case-report-and-key-learning-points"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.104920","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,9]]}}}